Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
进行中（未招募）
1
11.1%
已完成
2
22.2%
招募中
3
33.3%
终止
2
22.2%
Unknown
1
11.1%
暂无批准数据
- Enlivex Therapeutics announced a $212 million private placement to advance late-stage clinical development of Allocetra, a macrophage reprogramming therapy for osteoarthritis. - The company highlighted the significant unmet medical need, with over 32.5 million Americans and 300 million people worldwide affected by osteoarthritis, and no FDA or EMA-approved therapies capable of arresting structural joint damage. - Former Italian Prime Minister Matteo Renzi was appointed to the board of directors, bringing strategic leadership to the clinical-stage immunotherapy company. - The funding will support both the core clinical development program and a new digital asset treasury strategy centered on RAIN prediction markets.
• Initial data from Enlivex's Phase I/II trial shows Allocetra treatment resulted in 64% average pain reduction in patients with severe knee osteoarthritis who were candidates for knee replacement surgery. • One-third of treated patients experienced complete pain resolution, with pain scores dropping from an average of 9 to 0, demonstrating significant therapeutic potential. • The treatment demonstrated a favorable safety profile in this high-need patient population, marking a potential breakthrough for end-stage osteoarthritis management.
- Enlivex Therapeutics has dosed the first patient in a Phase I clinical trial evaluating Allocetra™ for psoriatic arthritis, with no initial safety concerns. - The trial aims to enroll six patients unresponsive to conventional treatments, assessing safety and changes in pain and disease activity over 12 months. - Allocetra™, an off-the-shelf cell therapy, seeks to reprogram macrophages to their homeostatic state, potentially offering a novel approach for inflammatory conditions. - The psoriatic arthritis treatment market is projected to reach $20.5 billion by 2032, highlighting the need for more effective and safer therapies.
- Enlivex Therapeutics reports positive interim efficacy data from its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis. - The data showed statistically significant improvements in key endpoints, including pain reduction and improved joint functionality, compared to baseline. - Enlivex has initiated the Phase II stage of the trial, a double-blind, randomized, placebo-controlled study to further assess Allocetra's efficacy and safety. - Allocetra aims to address the unmet need for treatments that can arrest or reverse the progression of osteoarthritis, which affects over 32.5 million Americans.
